NeoStrata patent suit
This article was originally published in The Rose Sheet
Executive Summary
Wilmington, Del. federal court rules that Valeant Pharmaceticals willfully infringed two patents held by TriStrata Technology, a subsidiary of NeoStrata, firm announces Nov. 25. Patents cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances." Jury verdict permits treble damages, TriStrata notes. Firm also filed a motion for permanent injunction Nov. 25 to prohibit the sale of infringing products, which include Valeant's Glyquin lines. TriStrata still has a lawsuit pending against Valeant related to another product, and also has filed suit against Mary Kay and BeautiControl. Chanel, Clarins and L'Oréal are among other companies that have been the targets of TriStrata patent infringement suits (1"The Rose Sheet" Aug. 30, 1999, p. 6)...
You may also be interested in...
Tristrata lawsuit
Valeant Pharmaceutical's motion seeking to overturn a jury verdict finding the company infringed two patents held by Tristrata Corporation and requesting a new trial is rejected by Wilmington, Del. federal court, according to parent company NeoStrata. Court also issues a permanent injunction prohibiting Valeant from the "manufacture, sale and marketing of products covered by the infringed patents." In November, the court ruled that Valeant willfully infringed the two patents, which cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances" (1"The Rose Sheet" Dec. 1, 2003, In Brief). Patent infringement suits are still pending against other firms including Mary Kay cosmetics and BeautiControl...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.